Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4945433 | 0.92 | DRD2 (0.36) | SLC6A3SLC6A4SLC6A2LIPGCHRM4 | |
| SCHEMBL4751794 | 0.90 | GRM2 (0.38) | LIPG | |
| SCHEMBL4693428 | 0.87 | CHEK2 (0.38) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL4745230 | 0.86 | MAOB (0.43) | SLC6A3SLC6A4LIPG | |
| SCHEMBL4947552 | 0.84 | CYP2D6 (0.39) | SLC6A3SLC6A4LIPG | |
| SCHEMBL4950186 | 0.83 | NPC1 (0.43) | SLC6A3SLC6A4SLC6A2CHRM4 | |
| SCHEMBL13993059 | 0.82 | DRD2 (0.43) | CHRM4 | |
| SCHEMBL4146888 | 0.79 | NPY1R (0.41) | — | |
| SCHEMBL4750532 | 0.77 | GRM2 (0.45) | SLC6A4 | |
| SCHEMBL4941482 | 0.76 | LIPG (0.36) | LIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| EP-1912989-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | claimed |
| WO-2007018998-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | claimed |
| CN-115485431-A | Treating agent for synthetic fiber, and method for treating synthetic fiber | 竹本油脂株式会社 | 2022-12-16 | — | — | CN | disclosed |
| CN-111764173-A | Treating agent for elastic fiber and elastic fiber | 竹本油脂株式会社 | 2020-10-13 | — | — | CN | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20070042916-A1 | METHODS FOR IMPROVED POWER TRANSMISSION PERFORMANCE AND COMPOSITIONS THEREFOR | AFTON CHEMICAL CORPORATION | 2007-02-22 | — | — | US | disclosed |
| WO-2007018998-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070000745-A1 | METHODS FOR IMPROVED POWER TRANSMISSION PERFORMANCE | AFTON CHEMICAL CORPORATION | 2007-01-04 | — | — | US | disclosed |
| US-20070004603-A1 | METHODS FOR IMPROVED POWER TRANSMISSION PERFORMANCE AND COMPOSITIONS THEREFOR | AFTON CHEMICAL CORPORATION | 2007-01-04 | — | — | US | disclosed |
| EP-1739158-A2 | Methods for improved power transmission performance and lubricating compositions therefor | Afton Chemical Corporation (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1739321-A2 | Methods for improved power transmission performance | Afton Chemical Corporation (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1739159-A2 | Methods for improved power transmission performance and lubricating compositions therefor | Afton Chemical Corporation (US) | 2007-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | GRM2, GRM1, GRIN2B | SLC6A3 122/4885SLC6A4 115/4885SLC6A2 143/4885 |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | GRM2, GRM1, GRIN2B | SLC6A3 122/4885SLC6A4 115/4885SLC6A2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.